Metronidazole shelgyl

SHELGYL® (Metronidazole)

Share this
Advertisement
Advertisement

SHELGYL® (Metronidazole)

Metronidazole is a Antiprotozoal, amoebicide indicated in amoebiasis, balantidiasis and Blastocystis hominis infection, giardiasis, dental infection, bacterial vaginosis and in sepsis due to anaerobic organisms such as Bacteroides spp. anaerobic cocci, notably post surgical infection, intra-abdominal infection, septicaemia, wound and pelvic infection, osteomylitis and abscess of lung or brain and in the prevention of postoperative anaerobic bacterial infections.

Dosage regimen and directions for use: As directed by the physician OR

Anaerobic infection usually treated for 7 days

  • Adult: 800mg initially, then 400mg every 8 hours
  • Children 7.5mg/kg body weight every 8 hours

Leg ulcers and pressure sores: 400mg every 8 hours for 7 days

Bacterial vaginosis: 400mg twice a day for 7 days or 2gm as a single dose

Acute ulcerative gingivitis

  • Adult: 200mg every 8 hours for 3 days
  • For children from 1-3 years: 50mg every 8 hours for 3 days
  • From 3-7 years: 100mg every 12 hours for 3 days
  • 7-10 years: 100mg every 8 hours for 3 days

Acute dental infection: 200mg every 8 hours for 3-7 days.

Contraindications

It is contraindicated in patients with blood dyscrasia or with active disease of central nervous system and also during pregnancy. It is also contraindicated in breast-feeding mothers and chronic alcohol dependency.

Side effects

Nausea, vomiting, unpleasant taste, furred tongue and gastrointestinal disturbances, rashes, urticaria, angioedema, rarely drowsiness, headache, ataxia, darkening of urine and anaphylaxis, on prolonged or intensive therapy peripheral neuropathy, transient epileptic form seizures and leucopenia.

Precautions and warnings

Disulfiram-like reaction with alcohol, hepatic impairment and hepatic encephalopathy, pregnancy and breast feeding, clinical and laboratory monitoring advised if treatment exceeds 10 days. Keep the medicine out of reach of children.

Share this

Leave a Comment

Your email address will not be published. Required fields are marked *

error: Content is protected !!